Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 04/20/2010 - 04/20/2013

This course is closed. Please look for other available products in CPNP University.

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Session Summary

Although first generation antipsychotics (FGAs) provided the bedrock of clinical treatment for people with schizophrenia for over 30 years, the advent of successive new drugs- second generation antipsychotics (SGAs)- led to a decline in use of FGAs in favor of SGAs that were (at least initially) perceived as both more efficacious and better tolerated.  While the relative merits of FGAs and SGAs remain hotly debated, it is now clear that the selection of an appropriate antipsychotic for any given patient represents a highly complex clinical decision-making process.

Personalized medicine remains some distance off currently for schizophrenia.  Additionally, federal policy and Institute of Medicine consensus collectively call for a more rapid translation of basic and clinical research findings into service delivery, a real gap currently in the treatment of schizophrenia.  Against that complex background, this session will tease out our current status with respect to the key clinical goal of seeking for each patient, the optimum balance between (high) efficacy and (high) tolerability in the context of pharmacotherapy with FGAs and SGAs.

The purpose and debate format of this symposium is consistent with this and seeks to provide attendees with a lively and interactive appreciation of the current psychopharmacology of schizophrenia.  Dr Nasrallah and Dr Buckley will pit themselves for/against sides on components of Efficacy (depressive symptoms, cognition, etc.) and side effects (TD, etc.) and will cover a spectrum of germane issues, also seeking out at the end of each section the input of the audience. This will be a highly interactive session, covering key aspects of psychopharmacology of current and emerging importance in schizophrenia.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • Receive a passing grade (60%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 60% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Peter Buckley, MD
Henry Nasrallah, MD

View biographical information and disclosures

Learning Objectives

  1. Identify the available literature regarding and differentiate the relative efficacy of typical and atypical antipsychotics used in patients with schizophrenia during the acute and maintenance phases of treatment.
  2. Identify the available literature regarding and differentiate the relative tolerability profiles of typical and atypical antipsychotics used in patients with schizophrenia during the acute and maintenance phases of treatment (considering morbidity and mortality, cost, and patient preference).
  3. Compare and contrast the risk-benefit ratio of typical and atypical antipsychotics in the treatment of schizophrenia.
  4. Discuss the importance of efficacy versus tolerability in the clinical decision making process for the individualized treatment of schizophrenia during the acute and maintenance phases.

Continuing Education Credit and Disclosures

Activity Dates: 04/20/2010 - 04/20/2013
ACPE Contact Hours: 2.0
ACPE Number: 0284-0000-10-012-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.10 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-10-012-L01-P (1.0 contact hours).

ACPE approved contact hours are accepted for ANCC Certification Renewal (see pages 5 and 6): At least 50% (37.5 hours) of your 75 continuing education hours must be formally approved continuing education hours. Formally approved continuing education hours meet one or more of the criteria listed below:

  1. Continuing nursing education (CNE) approved for nursing contact hours by an accredited provider or approver of nursing continuing education
  2. Continuing medical education (CME) approved for CME hours
  3. Sponsored by organizations, agencies, or educational institutions accredited or approved by the American Nurses Credentialing Center (ANCC) or the Accreditation Council for Continuing Medical Education (ACCME) or the Accreditation Council for Pharmacy Education (ACPE) or the Commission on Dietetic Registration

Grant Support

This programming was supported in part by grants from Bristol-Myers Squibb, Otsuka America Pharmaceutical, Inc., Lilly USA, LLC, AstraZeneca and Cyberonics.

Annual Meeting Grant Supporter

This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.